DNA-based immunization.

H L Davis, R G Whalen
{"title":"DNA-based immunization.","authors":"H L Davis,&nbsp;R G Whalen","doi":"10.1007/978-94-011-0547-7_18","DOIUrl":null,"url":null,"abstract":"<p><p>Over the past 2 years the principle of nucleic acid immunization has been demonstrated in several different animal models. Each of these was based on direct gene transfer using plasmid DNA into one or more tissues, with skeletal muscle being the preferred target. The expression vectors used to date have encoded antigens from several different viruses as well as a tumor-specific protein, an MHC class I molecule and a parasite antigen. It is clear that the induction of a broad range of immune responses is possible with DNA-based immunization, including the ability to confer protection against viral or parasitic challenge. In some cases, the immune response is superior to that obtained with traditional recombinant protein vaccination. For example, in the case of hepatitis B surface antigen, antibody appears earlier and levels rise more quickly with DNA-based than with recombinant protein vaccination (Davis et al., 1994). Despite the very promising beginning of this new approach, many issues remain to be examined before application to humans, especially those concerned with safety. In the meantime however, DNA-based immunization offers an extremely powerful tool for molecular immunologists to study the immune system and with which to develop new vaccines and other immunotherapeutic approaches. One can easily and rapidly clone and modify genes in plasmid DNA expression vectors, allowing many new constructs to be produced and tested in a short period of time which can be on the order of weeks. In contrast, the preparation of viral vectors, or the production and purification of recombinant proteins from bacteria, yeast or stably transfected mammalian cell lines, can easily take months to develop. The DNA-mediated induction of an immune response to a protein produced in situ has therefore initiated a new era of vaccine research. There is now the possibility to dramatically modify the way one approaches prophylactic vaccination, and as a consequence public health care can potentially be improved in a highly cost-effective manner.</p>","PeriodicalId":77271,"journal":{"name":"Molecular and cell biology of human diseases series","volume":"5 ","pages":"368-87"},"PeriodicalIF":0.0000,"publicationDate":"1995-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"39","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and cell biology of human diseases series","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/978-94-011-0547-7_18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 39

Abstract

Over the past 2 years the principle of nucleic acid immunization has been demonstrated in several different animal models. Each of these was based on direct gene transfer using plasmid DNA into one or more tissues, with skeletal muscle being the preferred target. The expression vectors used to date have encoded antigens from several different viruses as well as a tumor-specific protein, an MHC class I molecule and a parasite antigen. It is clear that the induction of a broad range of immune responses is possible with DNA-based immunization, including the ability to confer protection against viral or parasitic challenge. In some cases, the immune response is superior to that obtained with traditional recombinant protein vaccination. For example, in the case of hepatitis B surface antigen, antibody appears earlier and levels rise more quickly with DNA-based than with recombinant protein vaccination (Davis et al., 1994). Despite the very promising beginning of this new approach, many issues remain to be examined before application to humans, especially those concerned with safety. In the meantime however, DNA-based immunization offers an extremely powerful tool for molecular immunologists to study the immune system and with which to develop new vaccines and other immunotherapeutic approaches. One can easily and rapidly clone and modify genes in plasmid DNA expression vectors, allowing many new constructs to be produced and tested in a short period of time which can be on the order of weeks. In contrast, the preparation of viral vectors, or the production and purification of recombinant proteins from bacteria, yeast or stably transfected mammalian cell lines, can easily take months to develop. The DNA-mediated induction of an immune response to a protein produced in situ has therefore initiated a new era of vaccine research. There is now the possibility to dramatically modify the way one approaches prophylactic vaccination, and as a consequence public health care can potentially be improved in a highly cost-effective manner.

dna免疫。
在过去的两年中,核酸免疫原理已在几种不同的动物模型中得到证实。每一种方法都是利用质粒DNA将基因直接转移到一个或多个组织中,骨骼肌是首选目标。迄今为止使用的表达载体已经编码了来自几种不同病毒的抗原,以及一种肿瘤特异性蛋白、一种MHC I类分子和一种寄生虫抗原。很明显,基于dna的免疫可以诱导广泛的免疫反应,包括对病毒或寄生虫攻击提供保护的能力。在某些情况下,免疫应答优于传统的重组蛋白疫苗接种。例如,就乙型肝炎表面抗原而言,与重组蛋白疫苗相比,基于dna的疫苗抗体出现得更早,抗体水平上升得更快(Davis et al., 1994)。尽管这种新方法的开始非常有希望,但在应用于人类之前仍有许多问题需要研究,特别是那些与安全性有关的问题。与此同时,基于dna的免疫为分子免疫学家研究免疫系统和开发新疫苗和其他免疫治疗方法提供了一个极其强大的工具。人们可以很容易和快速地克隆和修改质粒DNA表达载体上的基因,允许在短时间内生产和测试许多新的结构,可能在几周左右。相比之下,病毒载体的制备,或者从细菌、酵母或稳定转染的哺乳动物细胞系中生产和纯化重组蛋白,很容易需要几个月的时间来开发。因此,dna介导的对原位产生的蛋白质的免疫反应的诱导开启了疫苗研究的新时代。现在有可能大大改变预防接种的方式,因此可以以极具成本效益的方式改善公共卫生保健。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书